Physician profile
Joseph E Lemlek
NPI 1932268265
$4,908.56
in general payments reported to CMS, 2019-2025
36 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $355 · 2021: $905 · 2022: $653 · 2023: $601 · 2024: $942 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,571.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,048.31 | 2019-2025 | Unify Assura, Jot Dx, Gallant |
| Astrazeneca Pharmaceuticals LP | $424.32 | 2019-2024 | Farxiga, Airsupra |
| Amgen INC. | $398.00 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $313.98 | 2020-2025 | Wegovy, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $250.60 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.55 | 2020-2025 | Jardiance |
| Abiomed | $235.94 | 2022-2025 | Impella |
| Merck Sharp & Dohme LLC | $234.50 | 2021-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $219.33 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $207.06 | 2021-2025 | |
| Edwards Lifesciences Corporation | $191.64 | 2022 | |
| Astellas Pharma US INC | $168.71 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $154.47 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $136.03 | 2021-2025 | |
| Amarin Pharma, INC. | $79.15 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $72.80 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $50.39 | 2021-2025 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $49.10 | 2024 | Arcalyst |
| Pfizer INC. | $46.81 | 2019-2025 | |
| Boston Scientific Corporation | $42.67 | 2021-2022 | |
| Scpharmaceuticals INC. | $41.00 | 2025 | |
| Inspire Medical Systems, INC. | $40.87 | 2024-2025 | Inspire |
| Medtronic, INC. | $37.87 | 2021-2022 | |
| United Therapeutics Corporation | $23.45 | 2025 | Orenitram, Remodulin |
| Medtronic Vascular, INC. | $20.45 | 2020 | |
| Penumbra, INC. | $20.00 | 2025 | Penumbra System |
| Kiniksa Pharmaceuticals, LTD. | $19.32 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $19.08 | 2023 | Inpefa |
| Bardy Diagnostics, INC. | $17.93 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.38 | 2019 | |
| Abbvie INC. | $16.28 | 2021 | |
| Csl Behring | $15.61 | 2021 | |
| Amryt Pharma Holdings LTD | $15.53 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.75 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $12.04 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Lemlek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.